[Form 4] Evoke Pharma Inc Insider Trading Activity

Rhea-AI Filing Summary

Evoke Pharma (EVOK) insider transaction: Roger Klein reported open‑market sales on 11/06/2025, including 5,000 shares at a weighted average price of $10.657 and 4,000 shares at $10.65.

After these trades, 29,000 shares were beneficially owned by his Roth IRA and 125,000 shares by the Krieger Charitable Trust, for which he is sole trustee. He disclaims beneficial ownership except to the extent of his pecuniary interest.

Insights

Corporate governance analyst

Routine Form 4 insider sale; neutral impact.

The filing lists open‑market sales by a company insider on 11/06/2025 at prices near $10.65. Such filings update the public record of insider holdings and trading but do not, by themselves, indicate strategic shifts.

The positions are held indirectly via a Roth IRA and a charitable trust, and the filer disclaims beneficial ownership beyond his pecuniary interest. Actual market impact depends on volume and liquidity; this excerpt provides only the disclosed trade sizes and prices.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klein Roger M.

(Last) (First) (Middle)

C/O CHOATE, HALL & STEWART

TWO INTERNATIONAL PLACE

(Street)

BOSTON MA 02110

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Evoke Pharma Inc [ EVOK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/06/2025		S		5,000	D	$10.657(1)	29,000	I(2)	By IRA
Common Stock	11/06/2025		S		4,000	D	$10.65	125,000	I(3)	By Krieger Charitable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Price reflects the weighted average sale price for the shares, which were sold in multiple transactions at prices that ranged from $10.65 to $10.66. Upon request, the Reporting Person will provide information regarding the number of shares sold at each price within the range to the Issuer, any security holder of the issuer, or the SEC staff.

2. Represents securities of the Issuer owned directly by Mr. Klein's Roth Individual Retirement Account ("IRA").

3. Represents securities of the Issuer owned directly by Krieger Charitable Trust (the "Trust"). Mr. Klein, as sole trustee of the Trust, may be deemed to beneficially own the securities of the Issuer owned directly by the Trust. Mr. Klein disclaims beneficial ownership of the securities of the Issuer reported herein, except to the extent of his pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Mr. Klein is a beneficial owner of the securities of the Issuer reported herein.

	/s/ Roger Klein	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did EVOK insider Roger Klein report on Form 4?

He reported open‑market sales on 11/06/2025 of 5,000 shares at a weighted average of $10.657 and 4,000 shares at $10.65.

What are Roger Klein’s reported EVOK holdings after the transactions?

Following the trades, 29,000 shares were held by his Roth IRA and 125,000 shares by the Krieger Charitable Trust.

How were the reported sale prices for EVOK shares determined?

The $10.657 reflects a weighted average from multiple trades between $10.65 and $10.66; details are available upon request.

What is the nature of Roger Klein’s ownership in the reported EVOK shares?

Holdings are indirect via a Roth IRA and the Krieger Charitable Trust; he disclaims beneficial ownership beyond his pecuniary interest.

Does this Form 4 indicate a 10b5-1 trading plan for EVOK shares?

The excerpt includes the 10b5‑1 checkbox language, but it does not indicate that the box was checked.